{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:09:34Z","timestamp":1778843374628,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","award":["118S397"],"award-info":[{"award-number":["118S397"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB TR128"],"award-info":[{"award-number":["SFB TR128"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011963","name":"European Academy of Neurology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.msard.2020.102376","type":"journal-article","created":{"date-parts":[[2020,7,4]],"date-time":"2020-07-04T18:35:19Z","timestamp":1593887719000},"page":"102376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2758-0207","authenticated-orcid":false,"given":"Berin","family":"Inan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahsan","family":"Gocmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-874X","authenticated-orcid":false,"given":"Atay","family":"Vural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse Ilksen","family":"Colpak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Meinl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asli","family":"Tuncer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2020.102376_bib0001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102376_bib0002","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102376_bib0003","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2020.102376_bib0004","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1590\/0004-282X20140032","article-title":"Seronegative neuromyelitis optica spectrum\u2013the challenges on disease definition and pathogenesis","volume":"72","author":"Sato","year":"2014","journal-title":"Arq. Neuropsiquiatr."},{"issue":"12","key":"10.1016\/j.msard.2020.102376_bib0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2020.102376_bib0006","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2020.102376_bib0007","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102376_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fneur.2020.00089","article-title":"Case series: myelin oligodendrocyte glycoprotein-immunoglobulin g-related disease spectrum","volume":"11","author":"Alshamrani","year":"2020","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102376_bib0009","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102376_bib0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/7651_2015_223","article-title":"Detection of autoantibodies against myelin oligodendrocyte glycoprotein in multiple sclerosis and related diseases","volume":"1304","author":"Spadaro","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"2","key":"10.1016\/j.msard.2020.102376_bib0011","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2020.102376_bib0012","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1212\/NXI.0000000000000625","article-title":"Identification of circulating MOG-specific B cells in patients with MOG antibodies","volume":"6","author":"Winklmeier","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"21","key":"10.1016\/j.msard.2020.102376_bib0013","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2020.102376_bib0014","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"Hoftberger","year":"2015","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2020.102376_bib0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2020.102376_bib0016","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102376_bib0017","article-title":"Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: a retrospective multicentric study","author":"Ciron","year":"2019","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2020.102376_bib0018","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102376_bib0019","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102376_bib0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.msard.2020.102376_bib0021","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","article-title":"MOG antibody-related disorders: common features and uncommon presentations","volume":"264","author":"Cobo-Calvo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102376_bib0022","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2020.102376_bib0023","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/practneurol-2017-001787","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations","volume":"19","author":"Jurynczyk","year":"2019","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.msard.2020.102376_bib0024","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.msard.2019.02.023","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder","volume":"30","author":"Salama","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2020.102376_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/WCO.0000000000000650","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder","volume":"32","author":"de Seze","year":"2019","journal-title":"Curr. Opin. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102376_bib0026","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2020.102376_bib0027","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00415-018-9122-2","article-title":"Neurological update: MOG antibody disease","volume":"266","author":"Wynford-Thomas","year":"2019","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.102376_bib0028","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the response to rituximab between myelin Oligodendrocyte glycoprotein and aquaporin-4 antibody diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102376_bib0029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/WNO.0000000000000669","article-title":"Unfavorable structural and functional outcomes in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis","volume":"39","author":"Jelcic","year":"2019","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.msard.2020.102376_bib0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.msard.2019.04.021","article-title":"Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease","volume":"32","author":"Tsantes","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102376_bib0031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2018.07.006","article-title":"Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis","volume":"25","author":"Tong","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2020.102376_bib0032","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40478-019-0786-3","article-title":"Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination","volume":"7","author":"Tea","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.msard.2020.102376_bib0033","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","author":"Waters","year":"2019","journal-title":"JAMA Neurol."}],"updated-by":[{"DOI":"10.1016\/j.msard.2020.102581","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000}}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030451X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030451X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:28:08Z","timestamp":1778840888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482030451X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":33,"alternative-id":["S221103482030451X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102376","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102376"}}